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Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.036We are delighted to provide readers of the Journal with this
review of major scientific work published in the field of
interventional cardiology in 2011, including late-breaking
trials presented at the American College of Cardiology,
Transcatheter Cardiovascular Therapeutics, European So-
ciety of Cardiology, and American Heart Association con-
ferences. We hope that the paper will provide a broad
overview for general cardiologists, as well as a framework for
more detailed study for those interested in interventional
cardiology.
Structural Heart Disease
Transcatheter aortic valve replacement. The Valve Aca-
demic Research Consortium (VARC) developed standard-
ized definitions for transcatheter aortic valve replacement
(TAVR) for clinical safety, procedure-related safety, clinical
efficacy, and composite endpoints (1). The PARTNER
(Placement of Aortic Transcatheter Valves) trial randomly
assigned 699 high operative risk patients (cohort A) with
symptomatic aortic stenosis to TAVR (SAPIEN Heart
Valve System, Edwards Lifesciences, Irvine, California) or
aortic valve replacement (AVR) (2). The primary endpoint
was all-cause mortality at 1 year (noninferiority). At 30 days,
TAVR was associated with a trend toward less mortality,
major bleeding, and New York Heart Association (NYHA)
functional class III/IV heart failure; similar risk of stroke
and permanent pacemaker (PPM); and greater risk of major
vascular complications and paravalvular aortic regurgitation
(PAR) 3. At 1 year, TAVR had similar mortality (Fig. 1)
and NYHA class III or greater heart failure; lower mean
transaortic valve gradient; and more PAR 3 (6.8% vs.
1.9%, p  0.001). The PARTNER trial included 358
patients with inoperable aortic stenosis (cohort B), ran-
domly assigned to TAVR or standard therapy; TAVR
resulted in better quality of life at 1 year (3).
In the European PARTNER (PARTNER EU) registry
of 130 patients with SAPIEN valves, TAVR success was
95%; 30-day and 6-month mortality was lower for trans-
femoral patients than for transapical patients (4). Investiga-
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Manuscript received December 13, 2011; accepted December 17, 2011tors in Germany evaluated early (n  150) and recent (n 
149) transapical SAPIEN experience (5); recent experience
had lower mortality at 30 days (11.3% vs. 6.0%, p  0.05)
and 1 year (30.0% vs. 21.5%, p  0.05), consistent with a
learning curve. The Edwards SAPIEN Aortic Bioprosthesis
European Outcome (SOURCE) registry reported 1-year
outcomes for 1,038 inoperable patients (6); 1-year mortality
was 23.9%, but was higher in transapical patients.
The German Transcatheter Aortic Valve Interventions
(TAVI) registry reported outcomes in 697 patients (CoreValve
[Medtronic, Minneapolis, Minnesota], n  588; SAPIEN
valve, n  109) (7). Technical success was achieved in
98.4%. Outcomes at 30 days included death (12.4%), stroke
(2.8%), and PPM (39.3%). The FRANCE (French Aortic
National CoreValve and Edwards) registry enrolled 244
patients (n  166 SAPIEN, n  78 CoreValve) (8).
Technical success was achieved in 98.3%. Outcomes at 30
days included death (12.7%), stroke (3.6%), acute coronary
occlusion (1.2%), and PPM (11.8%). The UK TAVI
(United Kingdom Transcatheter Aortic Valve implantation)
registry reported 2-year outcomes in 870 patients (n  452
CoreValve, n  410 SAPIEN valve, n  8 unknown) (9).
Compared to the SAPIEN valve, CoreValve was associated
with fewer conversions to surgical AVR (0% vs. 1.5%, p 
0.01), but more PAR 3 (17.3% vs. 9.6%, p  0.001),
repeat procedures (1.6% vs. 0%, p  0.02), and PPM
(24.4% vs. 7.4%, p 0.001). The Italian CoreValve registry
reported 1-year outcomes in 663 patients (10); procedural
success was achieved in 98.0%. The strongest independent
predictors of 30-day mortality were conversion to surgical
AVR (odds ratio [OR]: 38.68), tamponade (OR: 10.9), and
major vascular complications (OR: 8.47). The strongest
independent predictors of 1-year mortality were stroke (OR:
5.47), PAR 2 (OR: 3.79), pulmonary disease (OR: 2.7),
and renal disease (OR: 2.5). This registry reported outcomes
in 24 (3.6%) of 663 patients requiring immediate valve-in-
valve implantation for PAR (11). Compared to single valve
patients, valve-in-valve patients had more major adverse
events and higher mortality at 12 months (not statistically
significant). Another study evaluated 35 patients with aortic
annulus diameter 20 mm treated with a 23-mm SAPIEN
valve (12). Procedural success was achieved in 97.1%. There
was a significant decrease in transaortic valve gradient and
increase in orifice area, but 2 patients (5.9%) had severe
annular/prosthesis mismatch.
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81 (33.3%) of 243 patients required PPM at a mean of 4.0
days after TAVR (13). Pre-procedural atrioventricular block
(OR: 16.29) and increased QRS duration (OR: 3.45) were
the strongest independent predictors of PPM. Diffusion-
weighted magnetic resonance imaging was performed in
0 SAPIEN patients (14). New diffusion-weighted mag-
etic resonance imaging defects were identified in 68%,
imilar for transfemoral and transapical approaches. Most
vents were clinically silent, multiple, and bilateral. The
pectrum of stroke-related complications after surgical
VR and TAVR was the topic of a review (15). The
0-day risk of stroke was 1.5% after surgical AVR, 2% to
% after AVR for high-risk patients, and 1.5% to 6%
fter TAVR. The risks are highest at time of aortic
annulation and declamping during AVR, and at the time
f balloon aortic valvuloplasty (BAV), crossing the aortic
alve, and valve implantation during TAVR. After
AVR, 25% of strokes occur within 24 h, 50% within 1
o 7 days, and 25% within 7 to 30 days.
Significant annular/prosthesis mismatch can lead to
evere PAR, valve embolization, and aortic injury. One
tudy compared transthoracic echocardiography, cardiac
agnetic resonance (CMR), and cardiac computed to-
ography for annular sizing in 202 TAVR patients (16).
his study demonstrated better agreement for cardiac
omputed tomography and CMR than for transthoracic
chocardiography, and a strong association between PAR
nd larger annular dimensions by computed tomography
nd CMR, consistent with evolving impressions that the
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Figure 1 Primary Endpoint of Death From Any Cause After TAV
The primary endpoint of death from any cause after transcatheter aortic valve repl
randomized PARTNER (Placement of Aortic Transcatheter Valves) trial (2). CI  co
land Journal of Medicine.lliptical configuration of the annulus is more reliably assessed by cardiac computed tomography than by echo-
cardiography.
Mitral valve repair. An important review described the
evolution from edge-to-edge surgical mitral valve repair to
current transcatheter mitral valve repair (17). Another
review described the anatomy of the mitral valve and its
relationship to the coronary sinus and coronary arteries, the
percutaneous approaches to mitral annuloplasty, and the
percutaneous edge-to-edge repair using the MitraClip (Ab-
bott Vascular, Santa Clara, California) (18). Using detailed
echocardiographic and clinical criteria, 279 patients with
mitral regurgitation (MR) 3 were randomly assigned 2:1
to MitraClip or conventional surgery in the landmark
EVEREST-II (Endovascular Valve Edge-to-Edge Repair
Study) (19). The primary efficacy endpoint was freedom
from death, mitral valve surgery, and MR3 at 1 year. The
primary safety endpoint was major adverse events at 30
days. The primary efficacy endpoint was better for surgery
(73% vs. 55%, p  0.007), driven by less need for mitral
valve surgery (2.2% vs. 20.0%, p  0.001); the risks of
eath and MR 3 were similar. The primary safety
ndpoint at 30 days favored MitraClip (15% vs. 48%, p 
.001), driven by less blood transfusion (13% vs. 45%,
 0.001). At 1 year, there were compelling improve-
ents in left ventricle dimensions, volumes, and ejection
raction (EF) for both (the magnitude of improvement
avored surgery); quality of life was similar (but improved
aster after MitraClip); and MitraClip patients had less
YHA functional class III or greater (2% vs. 13%, p 
.002), but more MR 3 (19% vs. 4%, p  0.001).
atients 70 years of age, with degenerative MR, and EF
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April 24, 2012:1497–508 Year in Interventional CardiologyClip did not interfere with device explantation or subse-
quent mitral repair or replacement (20).
MitraClip was implanted in 104 patients with MR 3 and
NYHA functional class III or greater who were ineligible for
surgery (21). Device success was achieved in 92%, and resulted
in MR 2 in 82.5%. Echocardiography demonstrated signif-
cant improvement in LV volumes, regurgitant volumes, and
orward stroke volume. In the PERMIT-CARE (Percutane-
us Mitral Valve Repair in Cardiac Resynchronization Ther-
py) registry, MitraClip was inserted in 51 patients with severe
unctional MR who failed cardiac resynchronization therapy
22). Technical success was achieved in 100%, and there were
ighly significant improvements in left ventricle dimensions,
olumes, EF, NYHA functional class, and MR.
eft atrial appendage closure. The Watchman device
Atritech, Minneapolis, Minnesota) is designed to occlude
he left atrial appendage and reduce the risk of stroke in
atients with AF. Pooled data from the randomized PROTECT
F (Watchman Left Atrial Appendage System for Embolic
rotection in Patients with AF [n  542]) and the CAP
Watchman Continued Access Protocol [n  460]) trials
emonstrated a significant relationship between operator ex-
Figure 2 MACCE Rates According to Subset, Treatment Group
Time-to-event curves in the coronary artery bypass grafting (blue line) or percutane
(A) low (0 to 22), (B) intermediate (23 to 32), or (C) high (33) SYNTAX (Synergy
and cerebrovascular events (MACCE) in 3-vessel disease (3VD) patients with low,
left main disease (LM) with low, intermediate, or high SYNTAX scores (33). The
Heart Journal.erience and procedural success and safety (23). clective Percutaneous Coronary Intervention
he ACC/AHA/SCAI guidelines. The new American
ollege of Cardiology Foundation/American Heart Asso-
iation/Society for Cardiovascular Angiography and Inter-
entions (ACCF/AHA/SCAI) guidelines for percutaneous
oronary intervention (PCI) provide a comprehensive re-
iew of this rapidly evolving field (24). Important new areas
nclude ethical aspects of PCI, vascular access consider-
tions, hybrid revascularization, revascularization before
oncardiac surgery, optical coherence tomography, ad-
anced hemodynamic support devices, no-reflow therapies,
nd vascular closure devices. Full review of the guideline is
eyond the scope of this article. All interventional cardiol-
gists should read the entire document.
ppropriateness. There has been increasing attention re-
arding appropriateness of PCI procedures. An analysis of
00,154 PCI in the National Cardiovascular Data Registry
NCDR) showed that 98.6% of PCI for acute indications
ST-segment elevation myocardial infarction [STEMI],
on–ST-segment elevation myocardial infarction
NSTEMI], unstable angina with high-risk features) were
SYNTAX Score Category
oronary intervention (yellow line) overall cohorts to 3 years according to the
een PCI With Taxus and Cardiac Surgery) scores. (D to F) Major adverse cardiac
ediate, or high SYNTAX scores, respectively. (G to I) MACCE in patients with
lue is from the log-rank test. Reproduced with permission from the European, and
ous c
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Year in Interventional Cardiology April 24, 2012:1497–50850.4% were classified as appropriate, 38.0% as uncertain,
and 11.6% as inappropriate. There was substantial hospital
variation in the proportion of inappropriate PCI for non-
acute procedures. These data emphasize the importance of
careful case selection and clinical documentation, especially
in patients with stable ischemic heart disease.
Same-day discharge. With continued improvements in the
safety of PCI, there has been growing interest in discharg-
ing patients without overnight observation. Rao et al. (26)
reported outcomes in 107,018 Medicare patients undergo-
ing PCI, 1.25% of whom underwent same-day discharge.
Compared with overnight stay patients, there was no
difference in the incidence of death or rehospitalization
between days 2 and 30, suggesting that same-day discharge
is safe for carefully selected low-risk PCI patients.
Periprocedural myocardial infarction. Several articles in
2011 addressed the definition and clinical impact of
periprocedural myocardial necrosis. When comparing car-
diac enzyme measurements with myocardial injury on
CMR, creatine kinase–myocardial band allowed more ac-
curate diagnosis of periprocedural myocardial infarction
(MI), whereas troponin was oversensitive when applying the
universal definition (27). Among 6,347 PCI patients, only
large creatine kinase–myocardial band elevations (30 to 50
ng/ml) were associated with increased 1-year mortality (28).
Left main disease. Several publications assessed the safety
and efficacy of unprotected left main coronary artery stent-
ing compared to coronary artery bypass graft surgery
(CABG). Park et al. (29) randomly assigned 600 patients
with left main disease to CABG or a sirolimus-eluting stent
(SES). Major adverse cardiac events (MACE) were similar
at 1 year, but there was more ischemia-driven target vessel
revascularization (TVR) in the PCI arm at 2 years. In a
meta-analysis of 4 randomized trials of PCI compared with
CABG for left main disease (30), PCI was associated with
a nonsignificantly higher rate of 1-year MACE (14.5% vs.
11.8%, p  0.11) driven by more TVR. Stroke was less
frequent with PCI (0.1% vs. 1.7%, p  0.013). In the new
PCI guidelines, PCI of the left main has both Class IIa and
Class IIb recommendations depending on associated coro-
nary anatomy and patient characteristics (24). Among 509
drug-eluting stent (DES) patients, angiographic restenosis
occurred in 17% (31); predictors of restenosis included
female sex, diabetes mellitus, renal failure, more severe
disease, and distal bifurcation disease.
Multivessel disease. In a nonrandomized comparison of
3,042 patients (DES  1,547, CABG  1,495), mortality
was similar and revascularization was higher in DES pa-
tients at 5.6 years (32).
After 3-year follow-up in the SYNTAX (Synergy Be-
tween PCI With Taxus and Cardiac Surgery) trial, stent
thrombosis occurred in 4.1% of PCI-treated patients (33).
There were higher rates of MI (7.1% vs. 3.3%, p  0.005)
nd mortality (9.5% vs. 5.7%, p 0.02) with PCI; however,
his excess of events was confined to patients with interme-
iate (23 to 32) or high (33) SYNTAX scores (Fig. 2). Batients with a SYNTAX score 22 had similar outcomes
t 3 years, suggesting that PCI is an acceptable alternative to
ABG in patients with less complex disease. However,
atients treated with CABG had greater relief from angina
t 6 and 12 months (34).
edical therapy. In an analysis of 467,211 patients with
table coronary artery disease in the NCDR, fewer than half
eceived optimal medical therapy before PCI (aspirin, beta-
locker, and statin) (35).
At 3-year follow-up in the BARI-2D (Bypass Angio-
lasty Revascularization Investigation in Type 2 Diabetes)
rial, patients treated with initial revascularization had less
ngina and subsequent revascularization compared to med-
cally treated patients (36).
adial access. Two trials in 2011 compared outcomes
etween radial and femoral access. Jolly et al. (37) randomly
ssigned 7,021 patients with ACS; the primary composite
ndpoint of death, MI, stroke, or non–CABG-related
leeding at 30 days was similar (radial 3.7% vs. femoral
.0%). The incidence of major vascular complications was
ower with radial access. In 1,001 STEMI patients, radial
ccess was associated with fewer adverse events at 30 days
ompared with femoral access (13.6% vs. 21.0%, p 0.003)
38). In aggregate, these studies suggest that the radial
pproach should be the preferred strategy in primary PCI.
ifurcation. Kissing balloon dilation is often used to
optimize” the side branch. In the Nordic-Baltic Bifurcation
tudy III (39), 477 patients with successful main vessel
tenting (and side branch 2.25 mm) were randomly
ssigned to final kissing balloon post-dilation or no post-
ilation. Angiographic restenosis in the side branch was less
ith kissing balloon dilation; however, at 6 months, there
as no difference in clinical outcome between groups,
uggesting that routine kissing balloon post-dilation may
ot be necessary. In 370 patients with bifurcation lesions,
he double-kissing crush technique reduced angiographic
ide branch restenosis at 8 months, and TVR at 12 months
ompared with provisional stenting (40).
ein graft. The safety and efficacy of DES in saphenous
ein graft disease has been unclear. Mehilli et al. (41)
andomly assigned 610 patients with de novo saphenous
ein graft lesions to DES (SES or paclitaxel-eluting stent
PES]) or bare-metal stent (BMS) (41). At 1 year, the
rimary endpoint (death, MI, TLR [target lesion revascu-
arization]) was lower after DES (15% vs. 22%, p  0.02),
riven primarily by a reduction in TLR.
tent thrombosis. Stent thrombosis is an uncommon but
otentially devastating complication of PCI. Three genes
nvolved in clopidogrel metabolism and platelet receptor
unction were associated with stent thrombosis (CYP2C19,
BCB1, and ITGB3) (42). Peri-stent contrast staining
fter SES implantation was associated with subsequent
LR and very late stent thrombosis (43). At 2 years, definite
r probable stent thrombosis occurred in 4.4% patients after
rimary PCI, but there was no difference between DES and
MS (44).
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April 24, 2012:1497–508 Year in Interventional CardiologyIntravascular ultrasound. Intravascular ultrasound (IVUS)
is often performed to further characterize the severity of
angiographically intermediate left main stenosis. In a pro-
spective evaluation of 354 patients, a minimum lumen area
6 mm2 was shown to be a safe cutoff for deferring
revascularization (45).
Contrast-induced nephropathy. N-acetylcysteine is fre-
quently used to prevent contrast-induced nephropathy
(CIN); however, no benefit was found in a randomized trial
of 2,308 high-risk patients (46). In 450 STEMI patients,
early hydration with pre- and post-procedure bicarbonate
infusion was superior to either post-procedure isotonic
saline, and no hydration (incidence of CIN: 12% vs. 22.7%
vs. 27.3%, respectively; p for trend  0.001) (47). Adequate
volume expansion (960 ml) appeared to correlate with less
CIN. In a trial comparing RenalGuard (PLC Medical
Systems, Franklin, Massachusetts) to bicarbonate infusion
and N-acetylcysteine in 294 high-risk patients with esti-
mated glomerular filtration rate 30, CIN (increase of
0.3 mg/dl at 48 h) was less frequent with RenalGuard
(11% vs. 20.5%) (48).
Drug-Eluting Stents
DES thrombosis. In a 478-patient registry of DES stent
thrombosis, the majority of cases occurred after 1 year, and
presented with MI (67% STEMI, 22% NSTEMI) (49).
Nearly 30% of patients were taking dual-antiplatelet therapy
(DAPT) at the time stent thrombosis occurred. By histo-
logical analysis in 127 patients who died 1 month after
ES, localized strut hypersensitivity was seen with SES,
hereas malapposition secondary to excessive fibrin depo-
ition was seen with PES (50).
econd generation DES. Compared to first generation
ES, second generation DES (everolimus-eluting stent
EES]; zotarolimus-eluting stent [ZES]) reduce restenosis,
ut are more deliverable and have less stent thrombosis.
Numerous studies evaluating EES were published or
resented in 2011. In 1,800 patients randomly assigned to
n EES or PES, the 2-year incidence of MI, TVR, and
tent thrombosis was significantly lower with the EES (51).
imilar findings were reported by Stone et al. (52). Two
tudies demonstrated similar angiographic late loss with
ES and SES (53,54). In the RESET (Randomized Eval-
ation of Sirolimus-Eluting Versus Everolimus-Eluting Stent)
rial, 3,200 patients were randomly assigned to EES or SES;
LR at 1 year was similar (55). A propensity-matched analysis
eported less stent thrombosis with EES (56).
In a 5-year trial comparing ZES and SES, early angio-
raphic lumen loss was higher with ZES, but clinical
utcomes at 5 years favored ZES (MACE 14.0% vs. 22.2%,
 0.05) (57). Several studies evaluated the newer
esolute-ZES (Medtronic, Minneapolis, Minnesota),
hich was designed to provide a longer duration of drug
elease. In 1,402 patients, target lesion failure was 4.7% and
tent thrombosis was 0.1% at 12 months (58). (In a randomized trial comparing 2 second generation
ES (Resolute ZES vs. Xience EES), the safety and
fficacy of the 2 platforms were similar at 2 years in simple
nd complex lesion subsets (59,60).
ew polymers and coatings. In a randomized study of
,603 patients comparing biodegradable polymer DES with
ermanent polymer DES (SES or EES), similar clinical
utcomes were observed at 3 years (61). Another trial
eported similar MACE rates at 4 years between a biode-
radable polymer biolimus-eluting stent and a durable
olymer SES; however, there was less risk of very late stent
hrombosis with the biolimus-eluting stent (62).
In a first-in-human study with the Combo dual therapy
tent (biodegradable polymer with sirolimus on abluminal
urface; anti–CD-34 antibody layer on the luminal side),
ngiographic late loss at 9 months was 0.39 mm (noninfe-
ior to Taxus Liberté PES) (63). Promising results were also
eported with bioabsorbable polymer and everolimus ap-
lied only on the abluminal surface (64).
In contrast, a trial of an endothelial progenitor cell capturing
tent was terminated early due excess TVF at 1 year in the cell
apturing stent group compared with a DES (65).
olymer-free DES. Polymer residue has been implicated
s a potential etiology for late adverse events after DES. In
randomized trial of 3,002 patients, the polymer-free rapamy-
in and probucol-eluting stent was noninferior to a ZES
Endeavor Resolute) at 12 months (66). The Cre8 polymer-
ree SES had less late loss compared with PES (67).
ES restenosis. The optimal treatment strategy for DES
estenosis has not been well defined, but 2 studies suggested
hat a paclitaxel-eluting balloon is a promising option. In 50
atients with in-stent restenosis randomly allocated to
aclitaxel-eluting balloon versus conventional balloon an-
ioplasty, there was less late loss (0.18  0.45 mm vs.
.72  0.55 mm, p  0.001) and lower TLR (4.3% vs.
1.7%, p  0.003) after paclitaxel-eluting balloon (68).
nother trial also reported less late loss and restenosis after
aclitaxel-eluting balloon (69). Compared with focal in-
tent restenosis, diffuse in-stent restenosis was associated
ith more TLR (70).
ioresorbable scaffold. At 12 months, a second generation
ioresorbable EES had no change in scaffold area, late loss
f 0.27  0.32 mm, and 96.69% strut coverage by optical
oherence tomography (71). Implantation of a 3.0-mm
ioresorbable scaffold in smaller vessels appears to be safe
72). These findings represent an exciting step forward in
he field of bioresorbable vascular scaffolds.
cute Myocardial Infarction
CI after thrombolysis. Thiele et al. (73) randomly as-
igned 162 patients with long transfer times to pre-hospital
enecteplase before PCI or to primary PCI alone (all
atients 3 h acute myocardial infarction [AMI] onset).
lthough the facilitated PCI group had better TIMI
Thrombolysis In Myocardial Infarction) flow grade in the
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Year in Interventional Cardiology April 24, 2012:1497–508infarct-related artery, there was a trend toward larger infarct
size and more microvascular obstruction. A meta-analysis of
routine versus ischemia-guided PCI after initial fibrinolysis
reported that 30-day death, reinfarction, and ischemia were
lower after routine PCI (7.3% vs. 13.5%, p 0.0001) driven
by less reinfarction and ischemia (74).
Transfer. Several studies focused on optimizing the care of
STEMI patients who initially present to a hospital without
PCI. Wang et al. (75) reported that the median door-in to
door-out time was 68 min in a cohort of 14,821 STEMI
patients (75). Only 11% patients had a door-in to door-out
time 30 min (which has been established as a new clinical
performance measure). In 107,028 STEMI patients (12
h) treated with on-site fibrinolysis or transfer for primary
PCI, clinical outcomes were best when PCI-related delay
was 60 min (76). Importantly, there was no mortality
advantage for PCI if the delay to PCI exceeded 120 min.
Door-to-balloon times 90 min can be achieved in a rural
setting with implementation of protocols for rapid triage
and transfer of STEMI patients (77).
Drug-eluting stents. Although DES improve short-term
outcomes in STEMI patients compared to BMS, it is
unclear whether these benefits are sustained. In the
HORIZONS-AMI (Harmonizing Outcomes With Revas-
cularization and Stents in Acute Myocardial Infarction)
trial, PES resulted in a 40% reduction in ischemia-driven
TLR at 3 years (78). Although 1 study reported less TLR
with SES at 4 years, (79), another reported no difference in
clinical outcomes at 5 years with a PES (80). Of note, stent
thrombosis was similar between DES and BMS in all 3
studies.
Very late stent thrombosis (1 year) may occur as late as 11
years after primary PCI, and the frequency of very late stent
thrombosis is higher with DES (81). In 118 STEMI pa-
tients, optical coherence tomography at 1 year demonstrated
less neointimal hyperplasia, and more malapposition and
uncovered stent struts after PES compared with BMS (82).
Multivessel disease. Two studies evaluated culprit only
PCI, multivessel PCI in the same setting, or staged PCI for
STEMI patients with multivessel disease (83,84). Both
reported higher mortality with multivessel PCI in the same
setting, and the best outcomes were observed after staged
procedures.
Bleeding. In-hospital major bleeding is as an important
predictor of short-term mortality and clinical outcomes after
primary PCI. In 3,345 patients in the HORIZONS AMI
trial, patients with major in-hospital bleeding had higher
mortality (24.6% vs. 5.4%, p  0.0001) and more MACE
(40.3% vs. 20.5%, p 0.0001) at 3 years (85). Compared to
continuing unfractionated heparin plus a glycoprotein (GP)
IIb/IIIa receptor inhibitor, patients who were switched to
bivalirudin had less bleeding and improved late survival (86).
Adjunctive therapies. Previous studies suggested that
intra-aortic balloon pump counterpulsation before reperfu-
sion reduces myocardial injury. In 337 nonshock anterior
MI patients randomly assigned to intra-aortic balloon pumpbefore PCI versus primary PCI alone, there was no differ-
ence in infarct size at 3 to 5 days by CMR (87). Intravenous
erythropoietin given within 4 h of successful primary PCI did
not reduce infarct size, but was associated with more clinical
events (88).
Cell therapy. Several studies investigated intracoronary
infusion of mononuclear cells to improve ventricular func-
tion after STEMI. Administration of bone marrow or
peripheral mononuclear cells 3 to 8 days after large AMI did
not improve left ventricular volumes or infarct size at 4
months (89). In a small randomized trial (n  101),
myocardial viability improved after infusion of bone marrow
mononuclear cells 7 to 10 days after AMI (90). Late
administration of bone marrow mononuclear cells (2 to 3
weeks post-MI) to 87 patients with EF 45%, did not
improve global or regional left ventricle function or volumes
at 6 months (91).
Acute Coronary Syndromes
A focused update of the ACCF/AHA guidelines for man-
agement of patients with unstable angina and NSTEMI
presented new recommendations for: 1) antiplatelet therapy
including upstream use of GP IIb/IIIa inhibitor in high-risk
patients, use of prasugrel, maintenance dose and duration of
thienopyridines after PCI, and use of platelet function
testing and genotyping; 2) invasive versus conservative
management strategies; and 3) management of patients with
diabetes and chronic kidney disease (92).
Application of the SYNTAX score in patients with acute
coronary syndrome (ACS) undergoing PCI is recom-
mended as patients in the highest tertile of SYNTAX score
had higher mortality, MI, and TVR (93).
Pharmacotherapy
Clopidogrel. DUAL-ANTIPLATELET THERAPY. Several
tudies addressed the optimal duration of DAPT. In 1,443
ES patients, there was no difference in TVF (death, MI,
VR) for 6 months versus 12 months of DAPT (94).
ikewise, there was no difference in the composite of death,
I, and stroke at 2 years in another study of 2,013 patients,
ut there was significantly more bleeding after prolonged
APT (6 vs. 24 months) (95). A series of larger DAPT
rials are currently ongoing.
LOADING DOSE. Compared with a 300 mg loading dose in
STEMI patients, the 600 mg loading dose was associated
with smaller infarct size (96).
MAINTENANCE DOSE. Several studies suggested a direct
relationship between on-treatment platelet reactivity and
clinical outcomes (97,98). In a crossover study, clopidogrel
150 mg per day was shown to improve platelet inhibition
compared with clopidogrel 75 mg per day (99). Whether a
higher dosing strategy is beneficial in patients with subop-
timal platelet inhibition has been in question. Price et al.
(100) randomly assigned 2,214 patients with high residual
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dogrel to high-dose (150 mg daily) versus standard-dose
clopidogrel for 6 months (100). High-dose clopidogrel
caused a 22% reduction in platelet reactivity but did not
reduce clinical events.
GENOTYPE TESTING. The CYP2C19 polymorphisms have
been shown to impact the antiplatelet effect of clopidogrel
and may impact clinical outcomes. A point-of-care assay
was used to assess CYP2C19*2 carrier status (carriers
received prasugrel; noncarriers received clopidogrel) and
guide antiplatelet therapy (101). With this strategy, there
was a marked reduction in the proportion of CYP2C19*2
carriers with high on-treatment platelet reactivity (0% on
prasugrel vs. 30.4% on clopidogrel, p  0.009), suggesting
that genotype testing may play a role in determining the
optimal antiplatelet regimen after PCI.
Prasugrel. Seventy-six (25.2%) of 301 ACS patients who
were given a loading dose of prasugrel had suboptimal
platelet inhibition (measured within 6 to 12 h using the
vasodilator-stimulated phosphoprotein index), which was
associated with an increased risk of adverse events at 1
month (102). Prasugrel resulted in greater platelet inhibi-
tion than high-dose clopidogrel (600 mg loading dose, 150
mg maintenance) in diabetic patients (103), as well as
greater platelet inhibition than standard maintenance dose
clopidogrel in patients with high on-clopidogrel platelet
reactivity (104).
Ticagrelor. In the PLATO (Platelet Inhibition and Pa-
tient Outcomes) trial, ticagrelor reduced the risk of death,
MI, and stroke compared with clopidogrel in ACS patients,
but less benefit was observed in North America. This
geographic difference may have been due to higher doses of
aspirin in North America (105). Low-dose aspirin is cur-
rently recommended for patients receiving ticagrelor.
Cilostazol. Cilostazol is a selective phosphodiesterase-3
inhibitor with antiplatelet and antiproliferative properties.
After implantation of a long ZES (30 mm), addition of
cilostazol to aspirin and clopidogrel resulted in less late loss
and restenosis at 8 months (106). In 960 DES patients,
triple therapy resulted in greater platelet inhibition, but
there was no difference in the composite of death, nonfatal
MI, ischemic stroke, or TLR at 6 months (107).
Protease-activated receptor-1 inhibitors. Platelet activa-
tion can also occur through the protease-activated receptor
(PAR)-1 on the platelet surface. In a study of 12,944 ACS
patients randomly assigned to the oral PAR-I antagonist
vorapaxar or placebo, 58% underwent PCI (108). Vorapaxar
did not reduce the composite endpoint (cardiovascular
death, MI, stroke, hospitalization for ischemia, or urgent
revascularization) and was associated with more bleeding,
including intracranial hemorrhage. Atopaxar, another
PAR-1 inhibitor with a shorter half-life than vorapaxar, was
studied in ACS and stable CAD patients (109,110). Ato-
paxar resulted in greater platelet inhibition but no difference
in major bleeding. A dose-dependent transaminase eleva-tion and relative QTc prolongation were seen with the
highest dose of atopaxar.
Glycoprotein IIb/IIIa inhibitors. A meta-analysis of GP
IIb/IIIa in elective PCI (22 studies; n  10,123) showed no
difference in mortality, but less nonfatal MI in the GP
IIb/IIIa patients (111). There has been uncertainly about
the role of abciximab in patients with NSTEMI undergoing
PCI. Kastrati et al. (112) randomly assigned 1721
NSTEMI patients to abciximab and unfractionated heparin
versus bivalirudin. At 30 days, there was no difference in the
primary endpoint, a composite of death, large MI, or urgent
TVR, but there was more bleeding with abciximab (4.6% vs.
2.6%, p  0.02).
Previous studies suggested a possible benefit for intra-
coronary versus intravenous abciximab in primary PCI for
STEMI, but a randomized study in 2,065 STEMI patients
showed no difference in infarct size (peak creatine kinase
release), ST-segment resolution, or clinical outcomes (113).
Low-molecular-weight heparin. In a randomized trial of
intravenous enoxaparin (0.5 mg/kg with or without GP
IIb/IIIa inhibitor) versus UFH in primary PCI, the primary
endpoint (composite of death, complications of MI, proce-
dural failure, and non-CABG major bleeding at 30 days)
was lower with enoxaparin (28% vs. 34%, p 0.06) without
a difference in bleeding (114).
Factor Xa inhibitors. Several studies evaluated the role of
factor Xa inhibition in ACS, including 15,526 patients
randomly assigned to twice-daily doses of 2.5 mg or 5 mg
rivaroxaban or placebo (115). Approximately 60% of pa-
tients underwent PCI, and 90% received thienopyridines.
Both doses of rivaroxaban reduced the risk of the primary
composite endpoint (death, MI, or stroke at 30 days), and
the 2.5 mg dose (but not the 5 mg dose) was associated with
better survival at 13 months. However, rivaroxaban in-
creased the risk of major bleeding (2.1% vs. 0.6%, p 
0.001) and intracranial hemorrhage (0.6% vs. 0.2%, p 
0.009).
Apixaban was studied in ACS patients, the majority of
whom were also receiving DAPT (44% underwent PCI),
but the trial was terminated prematurely due to an increased
risk of major bleeding without reduction in ischemic events
(116). Finally, darexaban also resulted in a dose-related
increased risk of bleeding (117).
Statins. Statin pre-treatment reduces periprocedural MI
during elective PCI. In a meta-analysis of 13 randomized
trials (3,341 PCI patients), high-dose statin before PCI
resulted in a 44% reduction in periprocedural MI (creatine
kinase–myocardial band 3 times upper limit of normal),
and less 30-day MACE compared to low-dose statin or no
statin (118).
Proton pump inhibitors. There is controversy about the
use of proton pump inhibitors in patients requiring clopi-
dogrel. In a French registry of 3,670 MI patients, proton
pump inhibitor use was not associated with an increased risk of
death or cardiovascular events at 1 year, regardless of the type
of proton pump inhibitor or CYP2C19 genotype (119).
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Carotid disease. Studies of carotid artery stenting (CAS)
have reported the importance of operator experience on
outcomes, provided more insight into quality of life after
carotid revascularization, and proposed updated guidelines
for the management of carotid disease. In 3,388 asymptom-
atic patients in the CAPTURE 2 (Carotid ACCULINK/
ACCUNET Post Approval Trial to Uncover Rare Events)
registry, the combined risk of death and stroke at 30 days
was 3.3% (120). There was an inverse relationship between
adverse events and operator volume, and 72 CAS proce-
dures was the threshold to achieve death/stroke 3%. In a
Medicare database study of 24,701 CAS procedures, there
was an inverse relationship between mortality and operator
volume (121). A CREST (Carotid Revascularization End-
arterectomy Versus Stenting Trial) substudy evaluated qual-
ity of life after CAS and carotid endarterectomy (122). At 2
weeks and 30 days, CAS patients had significantly better
physical function; there were no differences at 1 year.
Periprocedural stroke had greater impact on quality of life
than did MI or cranial nerve injury.
Two trials evaluated proximal versus distal embolic pro-
tection devices (EPD); one randomly assigned 53 patients
with lipid-rich plaque to distal EPD (Filterwire EZ, Boston
Scientific, Santa Clara, California) or proximal EPD
(MO.MA, Invatec, Roacadelle, Italy) (123). Using trans-
cranial Doppler, there was less embolization with proximal
EPD. In the other study, 62 patients with symptomatic
stenosis were randomly assigned to distal EPD (Emboshield
Protection System, Abbott Vascular, Abbott Park, Illinois)
or proximal EPD with MO.MA (124). Using diffusion-
weighted magnetic resonance imaging, the number and
volume of new cerebral ischemic lesions were significantly
reduced by proximal EPD.
The 2011 American College of Cardiology Foundation/
American Heart Association Task Force on Practice Guide-
lines, and the American Stroke Association, American
Association of Neuroscience Nurses, American Association
of Neurological Surgeons, American College of Radiology,
American Society of Neuroradiology, Congress of Neuro-
logical Surgeons, Society of Atherosclerosis Imaging and
Prevention, Society for Cardiovascular Angiography and
Interventions, Society of Interventional Radiology, Society
of NeuroInterventional Surgery, Society for Vascular Med-
icine, and Society for Vascular Surgery guidelines (125)
developed the following recommendations for CAS: Class I
for CAS as an alternative to carotid endarterectomy in
symptomatic standard-risk patients with severe carotid ste-
nosis; Class IIa for CAS when revascularization is needed in
patients with unfavorable neck anatomy, and for EPD
during CAS; and Class IIb for CAS in highly selected
patients with asymptomatic severe carotid stenosis, and for
CAS or carotid endarterectomy in high-risk symptomatic or
asymptomatic patients (acknowledging that superiority to
medical therapy has not been demonstrated). The European aguidelines for extracranial carotid disease are incorporated
into the peripheral arterial disease (PAD) guidelines (126).
The European guidelines provide a Class IIa (rather than
IIb) recommendation for CAS for symptomatic high-risk
patients with severe carotid stenosis; a Class IIb recommen-
dation (rather than I) for symptomatic standard-risk pa-
tients; and Class IIb recommendation (rather than IIa) for
EPD during CAS.
Peripheral arterial disease. Studies of PAD have reported
new findings regarding medical and interventional manage-
ment of patients with claudication and critical limb ischemia
(CLI), as well as important new guidelines from the United
States and Europe. The CLEVER (Claudication: Exercise
Versus Endoluminal Revascularization) study randomly al-
located 111 patients with Rutherford class 1 to 3 claudica-
tion and aortoiliac PAD to optimal medical care, optimal
medical care and stent, or optimal medical care and super-
vised exercise (127). Supervised exercise achieved the great-
est increase in peak walking time, whereas stenting achieved
the greatest improvement in claudication-onset time, pe-
dometer walking, and quality of life. A single-center data-
base identified 360 endovascular CFA interventions, includ-
ing percutaneous transluminal balloon angioplasty (PTA),
stents for suboptimal PTA, and excisional atherectomy
(128). Outcomes at 1 year included restenosis in 27.6% and
TLR in 19.9%. Stents were independent predictors of
procedural success, and freedom from restenosis and TLR;
profunda involvement was predictive of procedural failure,
restenosis, and TLR.
The Zilver PTX randomized clinical study randomly
allocated 480 patients with symptomatic femoropopliteal
PAD to PTA or paclitaxel-coated Zilver PTX DES (Cook
Medical, Bloomington, Indiana); 120 PTA failures under-
went secondary randomization to DES or BMS (129).
Compared to PTA at 1 year, DES had better event-free
survival (90.4% vs. 82.6%, p  0.004), primary patency
(83.1% vs. 3.8%, p  0.001), and clinical benefit (88.3% vs.
75.8%, p 0.001). Compared to provisional BMS at 1 year,
provisional DES had better primary patency (89.9% vs.
73.0%, p  0.01) and clinical benefit (90.5% vs. 72.3%).
For infrapopliteal PAD, 161 patients with severe claudi-
cation or critical limb ischemia (CLI) were randomly
allocated to sirolimus-eluting stent (SES) or BMS (130).
The SES had better primary patency (80.6% vs. 55.6%, p 
.004), secondary patency (91.9% vs. 71.4%, p  0.005),
nd improvement in claudication (p  0.004). In another
tudy, 104 patients with severe claudication or CLI due to
nfrapopliteal PAD were treated with the In.Pact Am-
hirion paclitaxel-eluting balloon (Medtronic) (131). An-
iographic restenosis occurred in 27.4%, clinical improve-
ent in 91.2%, and limb salvage in 95.6% of patients.
The 2011 ACCF/AHA focused update of the guideline
or the management of patients with PAD (132) revised the
005 guidelines; there are new recommendations for report-
ng ankle-brachial index, smoking cessation, DAPT, and PTA
s an alternative to surgery for CLI patients. The European
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ment of PAD recommend an endovascular-first approach to
TASC (Trans-Atlantic Inter-Society Consensus) type A
through C lesions, if revascularization is indicated (133).
Hypertension. Interventional therapy appears promising for
refractory hypertension. In a 265-patient randomized trial,
carotid baroreceptor activation with the Rheos System (CVRx,
Minneapolis, Minnesota) was safe and resulted in improved
systolic blood pressure at 6 months (134). Bilateral renal
sympathetic denervation (Symplicity System, Medtronic) re-
duced blood pressure, fasting glucose, insulin levels, and
C-peptide levels in a 50-patient study at 3 months (135).
Reprint requests and correspondence: Dr. Simon R. Dixon,
Department of Cardiovascular Medicine, William Beaumont
Hospital, 3601 West 13 Mile Road, Royal Oak, Michigan 48073.
E-mail: sdixon@beaumont.edu.
REFERENCES
1. Leon MB, Piazza N, Kikolsky E, et al. Standardized endpoint
definitions for transcatheter aortic valve implantation clinical trials.
J Am Coll Cardiol 2011;57:253–69.
2. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical
aortic-valve replacement in high-risk patients. N Engl J Med 2011;
364:2187–98.
3. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of
life after transcatheter aortic valve replacement in inoperable patients
with severe aortic stenosis. Circulation 2011;124:1964–72.
4. Lefèvre T, Kappetein AP, Wolner E, et al. One year follow-up of the
multicentre European PARTNER transcatheter heart valve study.
Eur Heart J 2011;32:148–57.
5. Kempfert J, Rastan A, Holzhey D, et al. Transapical aortic valve
implantation: analysis of risk factors and learning experience in 299
patients. Circulation 2011;124 Suppl:124–9.
6. Thomas M, Schymik G, Walther T, et al. One-year outcomes of
cohort 1 in the Edwards SAPIEN aortic bioprosthesis European
outcome (SOURCE) registry. Circulation 2011;124:425–33.
7. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve
implantation: first results from a multicentre real-world registry. Eur
Heart J 2011;32:198–204.
8. Eltchaninoff H, Prat A, Gilard M, et al. Transcatheter aortic valve
implantation: early results of the FRANCE (French Aortic National
CoreValve and Edwards) registry. Eur Heart J 2011;32:191–7.
9. Moat NE, Ludman P, de Belder MA, et al. Long-term outcomes
after transcatheter aortic valve implantation in high-risk patients with
severe aortic stenosis. The UK TAVI (United Kingdom Transcath-
eter Aortic Valve Implantation) registry. J Am Coll Cardiol 2011;58:
2130–8.
10. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and
predictors of early and late mortality after transcatheter aortic valve
implantation in 663 patients with severe aortic stenosis. Circulation
2011;123:299–308.
11. Ussia GP, Barbanti M, Ramondo A, et al. The valve-in-valve
technique for treatment of aortic bioprosthesis malposition: an
analysis of incidence and 1-year clinical outcomes from the Italian
CoreValve registry. J Am Coll Cardiol 2011;57:1062–8.
12. Kalavrouziotis D, Rodés-Cabau J, Bagur R, et al. Transcatheter
aortic valve implantation in patients with severe aortic stenosis and
small aortic annulus. J Am Coll Cardiol 2011;58:1016–24.
13. Khawaja MZ, Rajani R, Cook A, et al. Permanent pacemaker
insertion after CoreValve transcatheter aortic valve implantation:
Incidence and contributing factors. Circulation 2011;123:951–60.
14. Rodés-Cabau J, Dumont E, Boone RH, et al. Cerebral embolism
following transcatheter aortic valve implantation: Comparison of
transfemoral and transapical approaches. J Am Coll Cardiol 2011;57:
18–28.15. Daneault B, Kirtane A, Kodali, S, et al. Stroke associated with
surgical and transcatheter treatment of aortic stenosis. J Am Coll
Cardiol 2011;58:2143–50.
16. Jabbour A, Ismail TF, Moat N, et al. Multimodality imaging in
transcatheter aortic valve implantation and post-procedural aortic
regurgitation. Comparison among cardiovascular magnetic reso-
nance, cardiac computed tomography, and echocardiography. J Am
Coll Cardiol 2011;58:2165–73.
17. Maisano F, La Canna G, Colombo A, et al. The evolution from
surgery to percutaneous mitral valve interventions: The role of the
edge-to-edge technique. J Am Coll Cardiol 2011;58:2174–82.
18. Feldman T, Cilingiroglu M. Percutaneous leaflet repair and annulo-
plasty for mitral regurgitation. J Am Coll Cardiol 2011;57:529–37.
19. Feldman T, Foster E, Glower DD, et al. Percutaneous repair or
surgery for mitral regurgitation. N Engl J Med 2011;364:1395–406.
20. Ladich E, Michaels M, Jones RM, et al. Pathological healing
response of explanted MitraClip devices. Circulation 2011;123:
1418–27.
21. Rudolph V, Knap M, Franzen O, et al. Echocardiographic and
clinical outcomes of MitraClip therapy in patients not amenable to
surgery. J Am Coll Cardiol 2011;58:2190–5.
22. Auuricchio A, Schillinger W, Meyer S, et al. Correction of mitral
regurgitation in nonresponders to cardiac resynchronization therapy
by MitraClip improves symptoms and promotes reverse remodeling.
J Am Coll Cardiol 2011;58:2183–9.
23. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left
atrial appendage closure: results from the Watchman left atrial
appendage system for embolic protection in patients with AF
(PROTECT AF) clinical trial and the Continued Access Registry.
Circulation 2011;123:417–24.
24. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/
SCAI guideline for percutaneous coronary intervention: executive
summary. A report of the American College of Cardiology Founda-
tion/American Heart Association Task Force on Practice Guidelines
and the Society for Cardiovascular Angiography and Interventions.
J Am Coll Cardiol 2011;58:e44–122.
25. Chan PS, Patel MR, Klein LW, et al. Appropriateness of percuta-
neous coronary intervention. JAMA 2011;306:53–61.
26. Rao SV, Kaltenbach LA, Weintraub WS, et al. Prevalence and
outcomes of same-day discharge after elective percutaneous coronary
intervention among older patients. JAMA 2011;306:1461–7.
27. Lim CC, van Gaal WJ, Testa L, et al. With the “universal
definition,” measurement of creatine kinase-myocardial band rather
than troponin allows more accurate diagnosis of periprocedural
necrosis and infarction after coronary intervention. J Am Coll Cardiol
2011;57:653–61.
28. Lindsey JB, Kennedy KF, Stolker JM, et al. Prognostic implications
of creatine kinase-MB elevation after percutaneous coronary inter-
vention. Circ Cardiovasc Interv 2011;4:474–80.
29. Park SJ, Kim YH, Park DW, et al. Randomized trial of stents versus
bypass surgery for left main coronary artery disease. N Engl J Med
2011;364:1718–27.
30. Capodanno D, Stone GW, Morice MC, et al. Percutaneous coronary
intervention versus coronary artery bypass graft surgery in left main
coronary artery disease. A meta-analysis of randomized clinical data.
J Am Coll Cardiol 2011;58:1426–32.
31. Lee JY, Park DW, Kim YH, et al. Incidence, predictors, treatment,
and long-term prognosis of patients with restenosis after drug-eluting
stent implantation for unprotected left main coronary artery disease.
J Am Coll Cardiol 2011;57:1349–58.
32. Park DW, Kim YH, Song HG, et al. Long-term comparison of
drug-eluting stents and coronary artery bypass grafting for multivessel
coronary revascularization. 5-year outcomes from the Asan Medical
Center-Multivessel Revascularization registry. J Am Coll Cardiol
2011;57:128–37.
33. Kappetein AP, Feldman TE, Mack MJ, et al. Comparison of
coronary bypass surgery with drug-eluting stenting for the treatment
of left main and/or three-vessel disease: 3-year follow-up of the
SYNTAX trial. Eur Heart J 2011;32:2125–34.
34. Cohen DJ, van Hout B, Serruys PW, et al. Quality of life after PCI
with drug-eluting stents or coronary-artery bypass surgery. N Engl
J Med 2011;364:1016–26.
1506 Dixon and Safian JACC Vol. 59, No. 17, 2012
Year in Interventional Cardiology April 24, 2012:1497–50835. Borden WB, Redberg RF, Mushlin AI, et al. Patterns and intensity
of medical therapy in patients undergoing percutaneous coronary
intervention. JAMA 2011;305:1882–9.
36. Dagenais GR, Lu J, Faxon DP, et al. Effects of optimal medical
treatment with or without coronary revascularization on angina and
subsequent revascularizations in patients with type 2 diabetes mellitus
and stable ischemic heart disease. Circulation 2011;123:1492–500.
37. Jolly SS, Yusuf S, Cairns J, et al. Radial versus femoral access for
coronary angiography and intervention in patients with acute coro-
nary syndromes (RIVAL): a randomised, parallel group, multicentre
trial. Lancet 2011;377:1409–20.
38. Romagnoli E. Radial versus femoral randomized investigation in ST
elevation acute coronary syndrome. The RIFLE STEACS study.
Paper presented at: Annual Meeting of Transcatheter Cardiovascular
Therapeutics 2011, November 10, 2011; San Francisco, CA.
39. Niemelä M, Kervinen K, Erglis A, et al. Randomized comparison of
final kissing balloon dilatation versus no final kissing balloon dilata-
tion in patients with coronary bifurcation lesions treated with main
vessel stenting. The Nordic-Baltic Bifurcation study III. Circulation
2011;123:79–86.
40. Chen SL, Santoso T, Zhang JJ, et al. A randomized clinical study
comparing double kissing crush with provisional stenting for treat-
ment of coronary bifurcation lesions. Results from the DKCRUSH-II
(Double Kissing Crush versus Provisional Stenting technique for
Treatment of Coronary Bifurcation Lesions) trial. J Am Coll Cardiol
2011;57:914–20.
41. Mehilli J, Pache J, Abdel-Wahab M, et al. Drug-eluting versus
bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a
randomised controlled superiority trial. Lancet 2011;378:1071–8.
42. Cayla G, Hulot JS, O’Connor SA, et al. Clinical, angiographic, and
genetic factors associated with early coronary stent thrombosis.
JAMA 2011;306:1765–74.
43. Imai M, Kadota K, Goto T, et al. Incidence, risk factors, and clinical
sequelae of angiographic peri-stent contrast staining after sirolimus-
eluting stent implantation. Circulation 2011;123:2382–91.
44. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors
of stent thrombosis after percutaneous coronary intervention for acute
myocardial infarction. Circulation 2011;123:1745–56.
45. de la Torre Hernandez JM, Hernandez F, Alfonso F, et al. Prospec-
tive application of pre-defined intravascular ultrasound criteria for
assessment of intermediate left main coronary artery lesions. Results
from the multicenter LITRO study. J Am Coll Cardiol 2011;58:
351–8.
46. ACT Investigators. Acetylcysteine for prevention of renal outcomes
in patients undergoing coronary and peripheral vascular angiography:
main results from the randomized acetylcysteine for contrast-induced
nephropathy trial (ACT). Circulation 2011;124:1250–9.
47. Maioli M, Toso A, Leoncini M, Micheletti C, Bellandi F. Effects of
hydration in contrast-induced acute kidney injury after primary
angioplasty. A randomized, controlled trial. Circ Cardiovasc Interv
2011;4:456–62.
48. Briguori C, Visconti G, Focaccio A, et al. Renal insufficiency after
contrast media administration trial II (REMEDIAL II): RenalGuard
system in high-risk patients for contrast-induced acute kidney injury.
Circulation 2011;124:1260–9.
49. Waksman R. The international FDA approved DES thrombosis
registry (DESERT). Paper presented at: Annual Meeting of Trans-
catheter Cardiovascular Therapeutics 2011, November 9, 2011; San
Francisco, California.
50. Nakazawa G, Finn A, Vorpahl M, et al. Coronary responses and
differential mechanisms of late stent thrombosis attributed to first
generation sirolimus- and paclitaxel-eluting stents. J Am Coll Cardiol
2011;57:390–8.
51. Smits PC, Kedhi E, Royaards KJ, et al. 2-year follow-up of a
randomized controlled trial of everolimus- and paclitaxel-eluting
stents for coronary revascularization in daily practice. COMPARE
(Comparison of the everolimus eluting XIENCE-V stent with the
paclitaxel eluting TAXUS LIBERTE stent in all-comers: a random-
ized open label trial). J Am Coll Cardiol 2011;58:11–8.
52. Stone GW, Rizvi A, Sudhir K, et al. Randomized comparison of
everolimus- and paclitaxel-eluting stents. 2-year follow-up from the
SPIRIT (clinical evaluation of the XIENCE V everolimus eluting
coronary stent system) IV trial. J Am Coll Cardiol 2011;58:19–25.53. Park KW, Chae IH, Lim DS, et al. Everolimus-eluting versus
sirolimus-eluting stents in patients undergoing percutaneous coro-
nary intervention. The EXCELLENT (Efficacy of Xience/Promus
versus Cypher to reduce late loss after stenting) randomized trial.
J Am Coll Cardiol 2011;58:1844–54.
54. Kim WJ, Lee SW, Park SW, et al. Randomized comparison of
everolimus-eluting stent versus sirolimus-eluting stent implantation
for de novo coronary artery disease in patients with diabetes mellitus
(ESSENCE-DIABETES): results from the ESSENCE-
DIABETES trial. Circulation 2011;124:886–92.
55. Kimura T. One-year clinical and angiographic outcomes from the
RESET trial. Randomized evaluation of sirolimus-eluting versus
everolimus-eluting stent trial. Presented at: European Society of
Cardiology Congress; August 2011; Paris, France.
56. Räber L, Jüni P, Nüesch E, et al. Long-term comparison of
everolimus-eluting and sirolimus-eluting stents for coronary revascu-
larization. J Am Coll Cardiol 2011;57:2143–51.
57. Kandzari D, Mauri L, Popma JJ, et al. Late-term clinical outcomes
with zotarolimus- and sirolimus-eluting stents. J Am Coll Cardiol
Intv 2011;4:543–50.
58. Yeung AC, Leon MB, Jain A, et al. Clinical evaluation of the
Resolute zotarolimus-eluting coronary stent system in the treatment
of de novo lesions in native coronary arteries. The RESOLUTE US
clinical trial. J Am Coll Cardiol 2011;57:1778–83.
59. Silber S, Windecker S, Vranckx P, et al. Unrestricted randomised use
of two new generation drug-eluting coronary stents: 2-year patient-
related versus stent-related outcomes from the RESOLUTE All
Comers trial. Lancet 2011;377:1241–7.
60. Stefanini GG, Serruys PW, Silber S, et al. The impact of patient and
lesion complexity on clinical and angiographic outcomes after revas-
cularization with zotarolimus- and everolimus-eluting stents. A
substudy of the RESOLUTE All Comers trial (a randomized
comparison of a zotarolimus-eluting stent with an everolimus-eluting
stent for percutaneous coronary intervention). J Am Coll Cardiol
2011;57:2221–32.
61. Byrne RA, Kastrati A, Massberg S, et al. Biodegradable polymer
versus permanent polymer drug-eluting stents and everolimus- versus
sirolimus-eluting stents in patients with coronary artery disease.
3-year outcomes from a randomized clinical trial. J Am Coll Cardiol
2011;58:1325–31.
62. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical
outcomes of biodegradable polymer biolimus-eluting stents versus
durable polymer sirolimus-eluting stents in patients with coronary
artery disease (LEADERS): 4-year follow-up of a randomised
non-inferiority trial. Lancet 2011;1940–8.
63. Haude M. The REMEDEE study. A randomized comparison of a
combination sirolimus eluting EPC capture stent with a paclitaxel eluting
stent. Paper presented at: Annual Meeting of Transcatheter Cardiovascular
Therapeutics 2011, November 11, 2011; San Francisco, CA.
64. Meredith IT. Clinical and angiographic outcomes of the EVOLVE
trial: a randomized evaluation of a novel Bioabsorbable polymer-
coated, everolimus-eluting coronary stent. Paper presented at: An-
nual Meeting of Transcatheter Cardiovascular Therapeutics 2011,
November 11, 2011; San Francisco, CA.
65. Massberg S, Byrne RA, Kastrati A, et al. Polymer-free sirolimus- and
probucol-eluting versus new generation zotarolimus-eluting stents in
coronary artery disease. The intracoronary stenting and angiographic
results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-
eluting stents (ISAR-TEST 5) trial. Circulation 2011;124:624–32.
66. Klomp M, Beijk MA, Varma C, et al. One-year outcome of TRIAS
HR (TRI-Stent Adjudication Study–High Risk of Restenosis). J Am
Coll Cardiol Intv 2011;4:896–904.
67. Carrie D. A prospective, randomized trial comparing Cre8, a
polymer-free stent eluting sirolimus, to a paclitaxel-eluting stent
(NEXT). Paper presented at: Annual Meeting of Transcatheter
Cardiovascular Therapeutics 2011, November 11, 2011; San Fran-
cisco, CA.
68. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-
eluting balloon catheter in patients with sirolimus-eluting stent
restenosis. J Am Coll Cardiol Intv 2011;4:149–54.
69. Rittger H. A prospective, randomized trial of a paclitaxel coated
balloon vs. uncoated balloon angioplasty in patients with drug-eluting
stent restenosis. PEPCAD-DES study. Paper presented at: Annual
11
1
1
1507JACC Vol. 59, No. 17, 2012 Dixon and Safian
April 24, 2012:1497–508 Year in Interventional CardiologyMeeting of Transcatheter Cardiovascular Therapeutics 2011,
November 11, 2011; San Francisco, CA.
70. Latib A, Mussardo M, Ielasi A, et al. Long-term outcomes after the
percutaneous treatment of drug-eluting stent restenosis. J Am Coll
Cardiol Intv 2011;4:155–64.
71. Serruys PW, Onuma Y, Dudek D, et al. Evaluation of the second
generation of a bioresorbable everolimus-eluting vascular scaffold for
the treatment of de novo coronary artery stenosis. 12-month clinical
and imaging outcomes. J Am Coll Cardiol 2011;58:1578–88.
72. Diletti R, Onuma Y, Farooq V, et al. 6-month clinical outcomes
following implantation of the bioresorbable everolimus-eluting vas-
cular scaffold in vessel smaller or larger than 2.5 mm. J Am Coll
Cardiol 2011;58:258–64.
73. Thiele H, Eitel I, Meinberg C, et al. Randomized comparison of
pre-hospital-initiated facilitated percutaneous coronary intervention
versus primary percutaneous coronary intervention in acute myocar-
dial infarction very early after symptom-onset. J Am Coll Cardiol
Intv 2011;4:605–14.
74. D’Souza SP, Mamas MA, Fraser DG, et al. Routine early coronary
angioplasty versus ischaemia-guided angioplasty after thrombolysis in
acute ST-elevation myocardial infarction: a meta-analysis. Eur
Heart J 2011;32:972–82.
75. Wang TY, Nallamothu BK, Krumholz HM, et al. Association of
door-in to door-out time with reperfusion delays and outcomes
among patients transferred for primary percutaneous coronary inter-
vention. JAMA 2011;305:2540–7.
76. Pinto DS, Frederick PD, Chakrabarti AK, et al. Benefit of transfer-
ring ST-segment-elevation myocardial infarction patients for percutane-
ous coronary intervention compared with administration of onsite
fibrinolytic declines as delays increase. Circulation 2011;124:2512–21.
77. Blankenship JC, Scott TD, Skelding KA, et al. Door-to-balloon times
under 90 min can be routinely achieved for patients transferred for
ST-segment elevation myocardial infarction percutaneous coronary in-
tervention in a rural setting. J Am Coll Cardiol 2011;57:272–9.
78. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a
glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and
paclitaxel-eluting stents versus bare-metal stents in acute myocardial
infarction (HORIZONS-AMI): final 3-year results from a multicen-
tre, randomised controlled trial. Lancet 2011;377:2193–204.
79. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of
TYPHOON (Trial to Assess the Use of the Cypher Sirolimus-
Eluting Coronary Stent in Acute Myocardial Infarction Treated
With Balloon Angioplasty). J Am Coll Cardiol Intv 2011;4:14–23.
80. Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after
primary percutaneous coronary intervention with a paclitaxel-eluting
stent versus a bare-metal stent in acute ST-segment elevation myocardial
infarction. J Am Coll Cardiol Intv 2011;4:24–9.
81. Brodie B, Pokharel Y, Fleishman N, et al. Very late stent thrombosis
after primary percutaneous coronary intervention with bare-metal
and drug-eluting stents for ST-segment elevation myocardial infarc-
tion. J Am Coll Cardiol Intv 2011;4:30–8.
82. Guagliumi G, Costa MA, Sirbu V, et al. Strut coverage and late
malapposition with paclitaxel-eluting stents compared with bare metal
stents in acute myocardial infarction. Circulation 2011;123:274–81.
83. Vlaar PJ, Mahmoud KD, Holmes DR, et al. Culprit vessel only
versus multivessel and staged percutaneous coronary intervention for
multivessel disease in patients presenting with ST-segment elevation
myocardial infarction. J Am Coll Cardiol 2011;58:692–703.
84. Kornowski R, Mehran R, Dangas G, et al. Prognostic impact of
staged versus “one-time” multivessel percutaneous intervention in
acute myocardial infarction. Analysis from the HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial. J Am Coll Cardiol 2011;58:704–11.
85. Suh JW, Mehran R, Claessen BE, et al. Impact of in-hospital major
bleeding on late clinical outcomes after primary percutaneous coronary
intervention in acute myocardial infarction. The HORIZONS-AMI
(Harmonizing Outcomes With Revascularization and Stents in Acute
Myocardial Infarction) trial. J Am Coll Cardiol 2011;58:1750–6.
86. Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching
antithrombin agents for primary angioplasty in acute myocardial
infarction. The HORIZONS-SWITCH analysis. J Am Coll Cardiol
2011;57:2309–16.
87. Patel MR, Smalling RW, Thiele H, et al. Intra-aortic balloon
counterpulsation and infarct size in patients with acute anteriormyocardial infarction without shock. The CRISP AMI randomized
trial. JAMA 2011;306:1329–37.
88. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in
patients with ST-segment elevation myocardial infarction. REVEAL: a
randomized controlled trial. JAMA 2011;305:1863–72.
89. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary
infusion of mononuclear cells from bone marrow or peripheral blood
compared with standard therapy in patients after acute myocardial
infarction treated by primary percutaneous coronary intervention:
results of the randomized HEBE trial. Eur Heart J 2011;32:1736–47.
90. Roncalli J, Mouquet F, Piot C, et al. Intracoronary autologous
mononucleated bone marrow cell infusion for acute myocardial
infarction: results of the randomized multicenter BONAMI trial. Eur
Heart J 2011;32:1748–57.
91. Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary
delivery of autologous bone marrow mononuclear cells 2 to 3 weeks
following acute myocardial infarction on left ventricular function.
The LateTIME randomized trial. JAMA 2011;306:2110–9.
92. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA
focused update of the guidelines for the management of patients with
unstable angina/non-ST-elevation myocardial infarction (updating
the 2007 guideline): a report of the American College of Cardiology
Foundation/American Heart Association task Force on Practice
Guidelines. J Am Coll Cardiol 2011;57:1920–59.
93. Palmerini T, Genereux P, Caixeta A, et al Prognostic value of the
SYNTAX score in patients with acute coronary syndromes undergo-
ing percutaneous coronary intervention. Analysis from the ACUITY
(Acute Catheterization and Urgent Intervention Triage Strategy)
trial. J Am Coll Cardiol 2011;57:2389–97.
94. Gwon HC. The randomized comparison of 6-month vs. 12-month
duration of dual anti-platelet therapy after the implantation of
drug-eluting stent. Paper presented at: Annual Meeting of the
American College of Cardiology, April 5, 2011; New Orleans, LA.
95. Valgimigli M. Prolonging dual antiplatelet treatment after grading
stent-induced intimal hyperplasia study (PRODIGY). Paper pre-
sented at: Annual Meeting of European Society of Cardiology,
August 30, 2011; Paris, France.
96. Patti G, Barczi G, Orlic D, et al. Outcome comparison of 600- and
300-mg loading doses of clopidogrel in patients undergoing primary
percutaneous coronary intervention for ST-segment elevation myocar-
dial infarction. Results from the ARMYDA-6 MI (Antiplatelet therapy
for reduction of myocardial damage during angioplasty-myocardial
infarction) randomized study. J Am Coll Cardiol 2011;58:1592–9.
97. Price MJ, Angiolillo DJ, Teirstein PS, et al. Platelet reactivity and
cardiovascular outcomes after percutaneous coronary intervention. A
time-dependent analysis of the gauging responsiveness with a Veri-
fyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS)
trial. Circulation 2011;124:1132–7.
98. Parodi G, Marcucci R, Valenti R, et al. High residual platelet
reactivity after clopidogrel loading and long-term cardiovascular
events among patients with acute coronary syndromes undergoing
PCI. JAMA 2011;306:1215–23.
99. Patti G, Grieco D, Dicuonzo G, et al. High versus standard
clopidogrel maintenance dose after percutaneous coronary interven-
tion and effects on platelet inhibition, endothelial function, and
inflammation. Results of the ARMYDA-150mg (Antiplatelet Ther-
apy for Reduction of Myocardial Damage During Angioplasty)
randomized study. J Am Coll Cardiol 2011;57:771–8.
00. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose
clopidogrel based on platelet function testing after percutaneous
coronary intervention. The GRAVITAS randomized trial. JAMA
2011;305:1097–105.
01. So D. Reassessment of anti-platelet therapy using an individualized
strategy based on genetic evaluation—the rapid gene study. Paper
presented at: Annual Meeting of Transcatheter Cardiovascular Ther-
apeutics 2011, November 9, 2011; San Francisco, CA.
02. Bonello L, Pansieri M, Mancini J, et al. High on-treatment platelet
reactivity after prasugrel loading dose and cardiovascular events after
percutaneous coronary intervention in acute coronary syndromes.
J Am Coll Cardiol 2011;58:467–73.
03. Angiolillo DJ, Badimon JJ, Saucedo JF, et al. A pharmacodynamic
comparison of prasugrel vs. high-dose clopidogrel in patients with
type 2 diabetes mellitus and coronary artery disease: results of the
11
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1508 Dixon and Safian JACC Vol. 59, No. 17, 2012
Year in Interventional Cardiology April 24, 2012:1497–508optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-3
trial. Eur Heart J 2011;32:838–46.
04. Trenk D. Primary results of testing platelet reactivity in patients
undergoing elective stent placement on clopidogrel to guide alterna-
tive therapy with prasugrel. (TRIGGER-PCI study). Paper pre-
sented at: Annual Meeting of Transcatheter Cardiovascular Thera-
peutics 2011, November 9, 2011; San Francisco, California.
05. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared
with clopidogrel by geographic region in the Platelet Inhibition and
Patient Outcomes (PLATO) trial. Circulation 2011;124:544–54.
06. Lee SW, Park SW, Kim YH, et al. A randomized, double-blind,
multicenter comparison study of triple antiplatelet therapy with dual
antiplatelet therapy to reduce restenosis after drug-eluting stent
implantation in long coronary lesions. Results from the DECLARE-
LONG II (Drug Eluting Stenting Followed by Cilostazol Treatment
Reduces Late Restenosis in Patients With Long Coronary Lesions)
trial. J Am Coll Cardiol 2011;1264–70.
07. Suh JW, Lee SP, Park KW, et al. Multicenter randomized trial
evaluating the efficacy of cilostazol on ischemic vascular complica-
tions after drug-eluting stent implantation for coronary heart disease.
Results of the CILON-T (influence of cilostazol-based triple anti-
platelet therapy on ischemic complication after drug-eluting stent
implantation) trial. J Am Coll Cardiol 2011;57:280–9.
08. Mahaffey KW. Vorapaxar, a platelet thrombin receptor antagonist, in
acute coronary syndromes (TRACER). Paper presented at: Annual
Meeting of the American Heart Association 2011, November 13,
2011; Orlando, FL.
09. O’Donoghue ML, Bhatt DL, Wiviott SD, et al. Safety and tolerability
of atopaxar in the treatment of patients with acute coronary syndromes.
The lessons from antagonizing the cellular effects of thrombin-acute
coronary syndromes trial. Circulation 2011;123:1843–53.
10. Wiviott SD, Flather MD, O’Donoghue ML, et al. Randomized trial
of atopaxar in the treatment of patients with coronary artery disease.
The lessons from antagonizing the cellular effect of thrombin-
coronary artery disease trial. Circulation 2011;123:1854–63.
11. Winchester DE, Wen X, Brearley WD, et al. Efficacy and safety of
glycoprotein IIb/IIIa inhibitors during elective coronary revascular-
ization. A meta-analysis of randomized trials performed in the era of
stents and thienopyridines. J Am Coll Cardiol 2011;57:1190–9.
12. Kastrati A. Abciximab plus heparin versus bivalirudin in patients with
NSTEMI undergoing PCI: ISAR- REACT 4 trial. Paper presented
at: Annual Meeting of the American Heart Association, November
13, 2011; Orlando, FL.
13. Thiele H. Intracoronary compared with intravenous bolus abciximab
application during primary percutaneous coronary intervention. The
abciximab intracoronary versus intravenously drug application in
ST-elevation myocardial infarction (AIDA STEMI) trial. Paper
presented at: Annual Meeting of the American Heart Association,
November 13, 2011; Orlando, FL.
14. Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or
unfractionated heparin in primary percutaneous coronary interven-
tion for ST-elevation myocardial infarction: the international ran-
domised open-label ATOLL trial. Lancet 2011;378:703.
15. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients
with a recent acute coronary syndrome. N Engl J Med 2012;
366:9–19.
16. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet
therapy after acute coronary syndrome. N Engl J Med 2011;365:
699–708.
17. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized,
double-blind, placebo-controlled trial of the safety and tolerability of
the novel oral factor Xa inhibitor darexaban (YM150) following acute
coronary syndrome. Eur Heart J 2011;32:2541–54.
18. Patti G, Cannon CP, Murphy SA, et al. Clinical benefit of statin
pretreatment in patients undergoing percutaneous coronary interven-
tion. A collaborative patient-level meta-analysis of 13 randomized
studies. Circulation 2011;123:1622–32.
19. Simon T, Steg PG, Gilard M, et al. Clinical events as a function of
proton pump inhibitor use, clopidogrel use, and cytochrome P450
2C19 genotype in a large nationwide cohort of acute myocardial
infarction. Results from the French registry of acute ST-elevation and
non-ST-elevation myocardial infarction (FAST-MI) registry. Circu-
lation 2011;123:474–82. i20. Gray WA, Rosenfield KA, Jaff MR, et al. Influence of site and
operator characteristics on carotid artery stent outcomes. Analysis of
the CAPTURE 2 (Carotid ACCULINK/ACCUNET Post Ap-
proval Trial to Uncover Rare Events) clinical study. J Am Coll
Cardiol Intv 2011;4:235–46.
21. Nallamothu BK, Gurm HS, Ting HH, et al. Operator experience
and carotid stenting outcomes in Medicare beneficiaries. JAMA
2011;306:1338–43.
22. Cohen DJ, Stolker JM, Wang K, et al. Health-related quality of life
after carotid stenting versus carotid endarterectomy. Results from the
CREST (Carotid Revascularization Endarterectomy Versus Stenting
Trial). J Am Coll Cardiol 201158:1557–65.
23. Montorsi P, Caputi L, Galli S, et al. Microembolization during
carotid artery stenting in patients with high-risk, lipid-rich plaque. A
randomized trial of proximal versus distal cerebral protection. J Am
Coll Cardiol 2011;58:1656–63.
24. Bijuklic K, Wandler A, Hazizi F, et al. Prevention of cerebral
embolization by proximal balloon occlusion compared to filter pro-
tection during carotid artery stenting: a prospective randomized trial.
J Am Coll Cardiol 2012;59:1383–9.
25. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/
AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/
SVS Guideline on the management of patients with extracranial
carotid and vertebral artery disease: executive summary. A report of
the American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines, and the American
Stroke Association, American Association of Neuroscience Nurses,
American Association of Neurological Surgeons, American College
of Radiology, American Society of Neuroradiology, Congress of
Neurological Surgeons, Society of Atherosclerosis Imaging and
Prevention, Society for Cardiovascular Angiography and Interven-
tions, Society of Interventional Radiology, Society of NeuroInterven-
tional Surgery, Society for Vascular Medicine, and Society for
Vascular Surgery. J Am Coll Cardiol 2011;57:1002–44.
26. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the
diagnosis and treatment of peripheral artery diseases. Eur Heart J
2011;32:2851–906.
27. Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise
versus primary stenting for claudication resulting from aortoiliac
peripheral artery disease. Six-month outcomes from the Claudication:
Exercise Versus Endoluminal Revascularization (CLEVER) study.
Circulation 2012;125:130–9.
28. Bonvini RF, Rastan A, Sixt S, et al. Endovascular treatment of
common femoral artery disease. J Am Coll Cardiol 2011;58:792–8.
29. Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show
superiority to balloon angioplasty and bare metal stents in femoro-
popliteal disease. Twelve-month Zilver PTX randomized study
results. Circ Cardiovasc Interv 2011;4:495–504.
30. Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs.
bare metal stents for treatment of focal lesions in infrapopliteal
arteries: a double-blind, multicentre, randomized clinical trial. Eur
Heart J 2011;32:2274–81.
31. Schmidt A, Piorkowski M, Werner M, et al. First experience with
drug-eluting balloons in infrapopliteal arteries. Restenosis rate and
clinical outcome. J Am Coll Cardiol 2011;58:1105–9.
32. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA focused
update of the guideline for the management of patients with peripheral
artery disease (updating the 2005 guideline): a report of the American
College of Cardiology Foundation/American Heart Association Task
Force on Practice Guidelines. J Am Coll Cardiol 2011;58;2020–45.
33. Tendera M, Aboyans V, Bartelink ML, et al. ESC guidelines on the
diagnosis and treatment of peripheral artery diseases. Eur Heart J
2011;32:2851–906.
34. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation
therapy lowers blood pressure in patients with resistant hypertension.
Results from the double-blind, randomized, placebo-controlled
Rheos pivotal trial. J Am Coll Cardiol 2011;58:765–73.
35. Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal
sympathetic denervation on glucose metabolism in patients with
resistant hypertension. A pilot study. Circulation 2011;123:1940–6.Key Words: aortic valve replacement y coronary artery y myocardial
nfarction y percutaneous intervention y stent.
